• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Merck

Merck

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Joining the Index Is No Way to Beat It

    Accepting indexlike performance without having indexlike costs is not a winning hand.

  2. UPDATE: Bull trend intact: S&P 500 rallies from the breakout point

    UPDATE: Bull trend intact: S&P 500 rallies from the breakout point

  3. UPDATE: Bull trend intact: S&P 500 rallies -2-

    UPDATE: Bull trend intact: S&P 500 rallies -2-

  4. Merck Announces Increased Quarterly Dividend

    Merck Announces Increased Quarterly Dividend

  5. Key Synaffix Patent Covering Glycan-Conjugated ADC Process Granted in the United States

    Key Synaffix Patent Covering Glycan-Conjugated ADC Process Granted in the United States

  6. AstraZeneca Says FDA Will Review Application for Bladder Cancer Drug

    AstraZeneca Says FDA Will Review Application for Bladder Cancer Drug

  7. Stocks Advance After Wall Street Highs -- 2nd Update

    Stocks Advance After Wall Street Highs -- 2nd Update

  8. Database of 200 Medical Device Distributors in Indonesia - Research and Markets

    Database of 200 Medical Device Distributors in Indonesia - Research and Markets

  9. Merck KGaA 3Q Net Income Rises 25.5%

    Merck KGaA 3Q Net Income Rises 25.5%

  10. Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors

    Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.